Hepatotoxicity of Rifampin and Pyrazinamide in the Treatment of Latent Tuberculosis Infection in HIV-Infected Persons: Is It Different Than in HIV-Uninfected Persons?
Open Access
- 15 August 2004
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 39 (4) , 561-565
- https://doi.org/10.1086/422724
Abstract
Background. In 2000, results of a multinational trial demonstrated that a 2-month course of rifampin and pyrazinamide (RZ) was as effective as isoniazid (INH) in reducing tuberculosis in human immunodeficiency virus (HIV)—infected individuals with latent tuberculosis infection (LTBI). After the release of new guidelines, the Centers for Disease Control and Prevention received reports of severe hepatotoxicity associated with the use of the RZ regimen for the treatment of LTBI in the general population. To better understand the occurrence of hepatotoxicity in an HIV-infected population, we conducted a more detailed analysis of the liver function test results obtained in the multinational trial of RZ. Methods. At study entry, patients were required to have a bilirubin level of ⩽2.5 mg/dL and both an aspartate aminotransferase (AST) level and an alkaline phosphatase level of ⩽5 times the upper limit of normal. Patients with acute hepatitis were excluded. At months 1 and 2 of the study, all patients had bilirubin and AST levels measured. Results. There was no difference between the RZ and INH groups with regard to AST level or bilirubin level at baseline. An increase in the AST level of ⩾40 U/L was associated with the use of INH and older age; and an increase in the bilirubin level of ⩾0.5 mg/dL was associated with the use of RZ, male sex, and nonwhite race (P < .05). An absolute AST level of >250 U/L occurred in 12 of 745 INH recipients and in 15 of 721 RZ recipients (P = .56), and an absolute bilirubin level of >2.5 mg/dL occurred in 5 of 743 INH recipients and 13 of 718 RZ recipients (P = .06). Conclusions. These data demonstrate very little liver injury associated with either INH or RZ in the HIV-infected subjects, leaving unclear the reasons for serious RZ-related liver damage in the general population.Keywords
This publication has 12 references indexed in Scilit:
- Incidence of Serious Side Effects from First-Line Antituberculosis Drugs among Patients Treated for Active TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Safety of 2 Months of Rifampin and Pyrazinamide for Treatment of Latent TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Pyrazinamide and Rifampin vs Isoniazid for the Treatment of Latent TuberculosisChest, 2003
- Safety and Tolerability of Intermittent Rifampin/Pyrazinamide for the Treatment of Latent Tuberculosis Infection in PrisonersJAMA, 2002
- Targeted Tuberculin Testing and Treatment of Latent Tuberculosis InfectionAmerican Journal of Respiratory and Critical Care Medicine, 2000
- Rifampin and Pyrazinamide vs Isoniazid for Prevention of Tuberculosis in HIV-Infected PersonsAn International Randomized TrialJAMA, 2000
- Twice weekly tuberculosis preventive therapy in HIV infection in ZambiaAIDS, 1998
- Aging and hepatotoxicity of isoniazid and rifampin in pulmonary tuberculosis.American Journal of Respiratory and Critical Care Medicine, 1995
- Isoniazid-associated Hepatitis Deaths: A Review of Available InformationAmerican Review of Respiratory Disease, 1992
- Adverse Effects of Antituberculosis DrugsDrugs, 1982